Plant compounds point to new paths for neuropathy treatment

Phytochemical-based Neuroprotection and In-silico Docking-driven Identification of Active Natural Compounds to Combat Neuropathy.

Current drug discovery technologies β€’ β€’ Related
πŸ€–

AI Summary

This review examined plant-derived compounds as possible treatments for neuropathic pain, a condition linked to damage or dysfunction in the body’s sensory nerves. Drawing on research published between 2000 and 2022, the authors combined a literature review with molecular docking studies and considered supporting laboratory and animal evidence. The findings suggest that phytochemicals may act through several routes, including antioxidant effects, reduced inflammation, altered neurotransmitter signaling, and regulation of pain-related ion channels.

The cannabis-relevant finding involved zerumbone, which showed predicted interactions with the cannabinoid receptors CB1 and CB2, with docking scores of -7.80 kcal/mol and -9.40 kcal/mol, respectively. The authors also identified icariin and aegeline as predicted lead compounds because of their interactions with NMDA and MAO targets. However, these are computational predictions rather than evidence that cannabis or these compounds relieve neuropathic pain in people. The study supports further laboratory, animal, and clinical researchβ€”but it does not establish a safe or effective cannabis-based treatment for users.

πŸ’‘ Key Findings

1
The review found that phytochemicals may provide multitarget neuroprotective effects, including antioxidant, anti-inflammatory, neurotransmitter-related, and ion-channel activity.
Moderate
50%
2
Zerumbone showed predicted binding to cannabinoid receptors CB1 and CB2, with docking scores of -7.80 kcal/mol and -9.40 kcal/mol.
Limited
35%
3
Icariin, aegeline, and zerumbone were identified as predicted lead molecules for further investigation against neuropathy-related targets.
Moderate
40%
4
The findings support using molecular docking alongside laboratory and animal studies to identify potential natural-product treatments, but they do not demonstrate clinical effectiveness or safety in humans.
Moderate
50%

πŸ“„ Original Abstract

Neuropathic pain, a devastating neurological disorder attributed to impairment or malfunctioning of the somatosensory system, affecting 10% of the world population. Current therapy emphasizes symptomatic management, featuring high-order side effects. Phytocompounds as neuroprotective agents are of growing interest, and can be screened using structure-based docking, and can act upon a variety of pathways with fewer adverse effects. A comprehensive literature survey was conducted covering studies published between 2000 and 2022 using scientific databases including PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar. The neuroprotective potential of medicinal plants and their bioactive phytochemicals was screened using in silico experiments targeting neuropathy-related molecular targets, followed by the evaluation of in vitro and in vivo activities. The studies showed that phytochemicals have multitarget neuroprotective activities, including antioxidant activity, modulation of neurotransmitter signaling, inhibition of inflammatory mediators, and modulation of neuropathic signaling ion channels. Several phytochemicals demonstrated notable binding affinities in docking studies, including icariin with NMDA receptors (-12.646 kcal/mol), aegeline with MAO-A (-10.06 kcal/mol) and MAO-B (-10.09 kcal/mol), and zerumbone with cannabinoid receptors CB1 (-7.80 kcal/mol) and CB2 (-9.40 kcal/mol). Other compounds, such as chlorogenic acid, myricetin, rutin, and piperine, also exhibited significant interactions with key neuropathic targets involved in neuroinflammation and pain signaling pathways. Docking studies identified that icariin, aegeline, and zerumbone are predicted lead molecules because they can interact with targets of interest, including NMDA, MAO, and CB receptors. Phytochemical neuroprotective drugs offer a promising approach to managing neuropathy. Integration of molecular docking approaches with experimental pharmacological studies provides a powerful strategy for identifying bioactive natural compounds with therapeutic potential. These findings support advancing phytochemicals as lead candidates for the development of safer, more effective treatments for neuropathy and neuropathic pain.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.